ADX 246
Alternative Names: ADX-246Latest Information Update: 25 Jul 2024
At a glance
- Originator Aldeyra Therapeutics
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Aldehyde inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Metabolic disorders
Most Recent Events
- 25 Jul 2024 Discontinued - Preclinical for Atopic dermatitis in USA (PO) (Aldeyra Therapeutics pipeline, July 2024)
- 25 Jul 2024 Discontinued - Preclinical for Metabolic disorders in USA (PO) (Aldeyra Therapeutics pipeline, July 2024)
- 16 Jan 2024 Preclinical trials in Metabolic disorders in USA (PO) prior to January 2024 (Aldeyra Therapeutics pipeline, January 2024)